Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer

LESSONS LEARNED. The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate‐resistant prostate cancer (mCRPC). The negative data underscore that, despite a sound biological ratio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Heath, Elisabeth, Heilbrun, Lance, Mannuel, Heather, Liu, Glenn, Lara, Primo, Monk, J. Paul, Flaig, Thomas, Zurita, Amado, Mack, Philip, Vaishampayan, Ulka, Stella, Philip, Smith, Daryn, Bolton, Susan, Hussain, Arif, Al‐Janadi, Anas, Silbiger, Daniel, Usman, Muhammad, Ivy, S. Percy
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738301/
https://ncbi.nlm.nih.gov/pubmed/31152080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0331
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados